Gilead Invests In Synthetic Biology Partnership For Next Gen CAR-Ts

Adapted Cells Can Sense Tumor Microenvironment

 
• By Andrew McConaghie
  
Gilead_USA
Gilead's Yescarta is set to exceed sales of $1bn for the first time this year, but could face 'off the shelf' competition soon. • Source: Gilead
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip